BASILEA PHARMACEUTICA AG

(BSLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about BASILEA PHARMACEUTICA AG
05/24TRANSCRIPT : Basilea Pharmaceutica AG Presents at UBS Global Healthcare Conference, May-24..
CI
04/27Basilea Pharmaceutica Licenses Antifungal Program From US-based Fox Chase
MT
04/27Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase..
AQ
04/27Basilea Pharmaceutica AG Announces Licensing of Novel First-In-Class Antifungal Program..
CI
04/13Basilea shareholders approve all proposals of the board of directors at the annual gene..
GL
04/13Basilea Pharmaceutica Ltd. Approves Appointment of Leonard Kruimer as New Member of Boa..
CI
04/13Basilea's Oncology Drug Candidates Show Anti-Cancer Activity in Preclinical Trial
MT
04/13Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and ..
AQ
04/13Basilea Pharmaceutica Ltd. Reports Preclinical Data on Oncology Drug Candidates BAL0891
CI
03/30BASILEA PHARMACEUTICA : Updated March 30, 2022
PU
03/16BASILEA PHARMACEUTICA : Shareholder letter EN
PU
03/08Basilea Pharmaceutica's BAL0891 Candidate Shows Anti-Cancer Activity in Preclinical Stu..
MT
03/08Basilea reports preclinical data on anti-cancer activity of novel oncology drug candida..
DJ
03/08Basilea Reports Preclinical Data on Anti-Cancer Activity of Novel Oncology Drug Candida..
CI
02/21BASILEA PHARMACEUTICA : Updated February  21, 2022
PU
02/15TRANSCRIPT : Basilea Pharmaceutica AG, 2021 Earnings Call, Feb 15, 2022
CI
02/15Basilea Pharmaceutica AG Reports Earnings Results for the Full Year Ended December 31, ..
CI
02/15BASILEA PHARMACEUTICA : Updated February  15, 2022
PU
02/15Basilea Pharmaceutica Initiates Strategic Review of Oncology Assets
MT
02/15Basilea Pharmaceutica's Net Loss Shrinks in FY21 on Anti-Infectives Boost
MT
02/15Basilea to become a leading anti-infectives company backed by strong financial results ..
DJ
02/15Basilea Pharmaceutica AG Provides Earnings Guidance for the Fiscal Year 2022
CI
01/24Basilea Pharmaceutica's Derazantinib Shows High Disease Control Rate in Bile Duct Cance..
MT
01/24BASILEA PHARMACEUTICA : Updated January 24, 2022
PU
01/24Basilea reports updated interim results for iCCA patients with FGFR2 mutations and ampl..
DJ
01/24Basilea Reports Updated Interim Results for iCCA Patients with FGFR2 Mutations and Ampl..
CI
01/13Basilea-Pfizer's Cresemba Gets China's Approval to Treat Another Fungal Infection
MT
01/13Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergi..
AQ
01/13Basilea announces approval of antifungal Cresemba(R) (isavuconazole) for invasive asper..
DJ
01/11Basilea Completes Patient Enrolment For New Antibiotic Study
MT
01/11BASILEA PHARMACEUTICA : Updated January 11, 2022
PU
01/11Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigat..
DJ
01/11Basilea Announces Completion of Patient Enrolment in Phase 3 Eradicate Study Investigat..
CI
01/10Basilea Pharmaceutica's Preliminary FY21 Revenue Beats Estimates
MT
01/10BASILEA PHARMACEUTICA : Updated January 10, 2022
PU
01/10Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-positi..
DJ
01/10Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2021
CI
01/07BASILEA PHARMACEUTICA : Updated January 07, 2022
PU
01/07Basilea To Get $16 Million From Astellas After Strong Antifungal Drug Sales In US
MT
01/07Strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million s..
AQ
01/07Strong Cresemba(R) (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million..
DJ
01/06Basilea Expects Late-Stage Data for Anti-Bacterial Drug by Mid-2022
MT
01/06BASILEA PHARMACEUTICA : Updated January 06, 2022
PU
01/06Basilea reports on portfolio progress made in 2021
DJ
2021Basilea Gets $10 Million From Pfizer After Chinese Approval of Antifungal Cresemba
MT
2021Basilea receives USD 10 million milestone payment related to approval of antifungal Cre..
AQ
2021Basilea receives USD 10 million milestone payment related to approval of antifungal Cre..
DJ
2021BASILEA PHARMACEUTICA : Updated December 17, 2021
PU
2021Basilea Wins US FDA Nod For Early-Stage Study Of New Cancer Drug
MT
2021Basilea announces FDA approval of Investigational New Drug application for novel oncolo..
DJ
2021Basilea Pharmaceutica Ltd. Announces FDA Approval of Investigational New Drug Applicati..
CI
2021Basilea Pharmaceutica Receives $10 Million Milestone Payment from Pfizer
MT
2021Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 10 million sales..
AQ
2021Continued strong Cresemba(R) (isavuconazole) sales by Pfizer trigger USD 10 million sal..
DJ
2021Basilea Seeks US FDA's Investigational New Drug Approval For Cancer Therapy
MT
2021BASILEA PHARMACEUTICA : Updated November 16, 2021
PU
2021Basilea announces submission of Investigational New Drug application for novel oncology..
DJ
2021Basilea Pharmaceutica Ltd Announces Submission of Investigational New Drug Application ..
CI
2021BASILEA PHARMACEUTICA : Therapy Shows Synergistic Anti-Tumor Effects In Gastric Cancer Mod..
MT
2021Basilea presents preclinical data on synergy between derazantinib and paclitaxel in gas..
DJ
2021Basilea Pharmaceutica Ltd Presents Preclinical Data on Synergy Between Derazantinib and..
CI
2021BASILEA PHARMACEUTICA : Asahi Kasei Seek Japanese Nod For Anti-Fungal Drug
MT
2021Basilea's partner Asahi Kasei Pharma filed New Drug Application for the marketing autho..
DJ
2021BASILEA PHARMACEUTICA : partner Asahi Kasei Pharma filed New Drug Application for the mark..
AQ
2021BASILEA PHARMACEUTICA : Bile Duct Cancer Drug Shows Improved Efficacy In Updated Mid-Stage..
MT
2021Basilea presents full safety and efficacy data set on derazantinib in patients with FGF..
DJ
2021Basilea Pharmaceutica Ltd. Presents Full Safety and Efficacy Data Set on Derazantinib i..
CI
2021TRANSCRIPT : Basilea Pharmaceutica AG, H1 2021 Earnings Call, Aug 17, 2021
CI
2021Basilea Pharmaceutica Ag Reports Earnings Results for the Half Year Ended June 30, 2021
CI
2021BASILEA PHARMACEUTICA : reports strong financial results for half-year 2021 with significa..
AQ
2021Basilea Pharmaceutica AG Provides Earnings Guidance for the Full Year 2021
CI
2021BASILEA PHARMACEUTICA : Wins Additional $4.3 Million US Funding to Develop Antibiotic
MT
2021Basilea awarded additional USD 4.3 million by BARDA to support phase 3 development of c..
DJ
2021BASILEA PHARMACEUTICA : Gets US FDA's Orphan Drug Designation For Brain Cancer Treatment
MT
2021Basilea announces U.S. FDA Orphan Drug Designation granted to lisavanbulin for the trea..
DJ
1  2  3  4  5  6  7  8Next
Upcoming event on BASILEA PHARMACEUTICA AG